Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019

• Main Authors: Natthaphat Siri-Angkul, Siriporn C. Chattipakorn, Nipon Chattipakorn
• Format: Journal
• Published: 2020
• Subjects: Biochemistry, Genetics and Molecular Biology
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089457137&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/70161
• Institution: Chiang Mai University

© 2020 The Authors. The Journal of Physiology © 2020 The Physiological Society The coronavirus disease 2019 (COVID-19) is the third major coronavirus outbreak of this century. Its aetiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could affect SARS-CoV-2 infectivity and may alter COVID-19 disease progression by altering ACE2 expression. Current evidence of ACEI/ARB-ACE2 interaction as well as the effects of ACEIs/ARBs on viral-associated acute lung injury is summarized and discussed in this review. This review assesses the evidence gathered so far and highlights the research that needs to be done to help inform clinical decision making. (Figure presented.).